Table 3 Synergistic effects of TAI-1 with cytotoxic agents
From: Characterization of the biological activity of a potent small molecule Hec1 inhibitor TAI-1
Drug | Cell lines | Drug 1 GI50(nM) | TAI-1 GI50(nM) | Drug 1: TAI-1 GI50ratio | Combination index | Synergy |
|---|---|---|---|---|---|---|
Doxorubicin | K562 | 36 | 44 | 0.83 | 0.66 | Yes |
MDA-MB-468 | 27 | 34 | 0.80 | 0.87 | Yes | |
Huh7 | 183 | 84 | 2.17 | 0.73 | Yes | |
Topotecan | MDA-MB-231 | 347 | 43 | 8.01 | 0.78 | Yes |
MDA-MB-468 | 11 | 34 | 0.32 | 0.74 | Yes | |
Paclitaxel | Huh7 | 94 | 84 | 1.11 | 0.28 | Yes |
MDA-MB-231 | 5 | 42 | 0.12 | 0.68 | Yes | |
K562 | 10 | 41 | 0.24 | 0.73 | Yes | |
Sorafenib | Huh7 (liver) | 4501 | 84 | 53.38 | 1.66 | Antagonistic |
Hep3B (liver) | 3676 | 104 | 35.50 | 1.50 | Antagonistic | |
KXO1 | Huh7 (liver) | 27 | 84 | 0.32 | 1.31 | Additive |